30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Bone Therapeutics Reports Results of Viscosupplement Study -

Bone Therapeutics’ first efficacy study of the JTA-004 viscosupplement to treat knee osteoarthritis showed that a single injection delivered higher pain reduction between baseline and six months post-treatment vs. a reference product (hylan G-F 20). JTA-004 is a patented, non-cellular viscosupplement product for the treatment of knee osteoarthritis, which Bone Therapeutics has been developing in parallel with its core cell therapy pipeline. Next steps in the commercialization of JTA-004 include future clinical development and dialogue with regulatory authorities. (Bone Therapeutics, 10/17/18)